All In Biotech

Drug Trial Radar · NCT06712082

A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants

A Phase 1, Randomized, Double-Blind, Third-Party Open, Placebo-Controlled, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immunogenicity, and Pharmacodynamics Following Intravenous Dose of PF-07264660 in Chinese Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

12

Actual

Start

Feb 24, 2025

Primary completion

Sep 4, 2025

Study completion Sep 4, 2025

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn if the study medicine (called PF-07264660) is safe and how it is processed in healthy Chinese participants. This study is seeking participants who: * are between 18 to 65 years of age. * are Chinese participants who are overtly healthy as determined by medical evaluation. * have a BMI (body mass index) of 19 to 28 kilogram per meter squared; and a total body weight of more than50 kilograms (110 pounds). All participants in this study will receive study medicine. Three-fourths will receive PF-07264660 and one-fourth will receive placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. The study medicine will be given as an IV infusion (directly into a vein) at the study clinic only one time. The study will compare the experiences of people receiving PF-07264660 to those of people who do not. This will help see if PF-07264660 is safe and how it behaves inside the human body. Participants will take part in this study for up to 181 days. During this time, the participants will stay at the study clinic for 5 days. After the stay, the participants will have 8 study visits at the study clinic.

Conditions

  • Healthy

Interventions

  • PF-07264660Drug

    PF-07264660 solution for injection (single use only)

  • PlaceboOther

    Placebo solution for injection (single use only)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 181
  2. Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: Up to Day181
  3. area under the concentration-time curve from time 0 to 336 hours (AUC336)Time frame: Up to Day 181
  4. area under the concentration-time curve from time 0 to infinity (AUCinf)Time frame: Up to Day 181
  5. area under the concentration-time curve from 0 to time of last measurable concentration (AUClast)Time frame: Up to Day 181
  6. Terminal phase half-life (t½)Time frame: Up to Day 181
  7. Incidence of treatment-emergent adverse events (TEAEs)Time frame: Up to Day 181
  8. Incidence of treatment-emergent serious adverse events (SAEs)Time frame: Up to Day 181
  9. Incidence of abnormal and clinically relevant changes in vital signsTime frame: Up to Day 181
  10. Incidence of abnormal and clinically relevant changes in electrocardiogramTime frame: Up to Day 181
  11. Incidence of abnormal and clinically relevant changes in laboratory assessmentsTime frame: Up to Day 181

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital,Fudan University

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital,Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.